|
시장보고서
상품코드
2132346
노인황반변성 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 질환별, 유통 채널별, 지역별 및 부문별 예측(2026-2033년)Age-related Macular Degeneration Market Size, Share & Trends Analysis Report By Product, By Disease, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
노인황반변성 시장 요약
세계의 노인황반변성 시장 규모는 2025년에 116억 달러로 평가되며, 2026년 125억 달러에서 2033년까지 227억 달러로 확대될 것으로 예상되며, 2026년부터 2033년까지 CAGR은 9.0%에 달할 것으로 예측됩니다.
2025년에는 북미 시장이 매출 점유율의 53.9%를 차지하며 시장을 주도했습니다. 노인황반변성(AMD)은 고령층의 돌이킬 수 없는 시력 상실의 주요 원인 중 하나로 남아 있기 때문에 고령화에 따른 부담 증가가 시장 성장을 뒷받침하고 있습니다.
이 시장은 질환에 대한 인식 제고, 광간섭단층촬영(OCT) 등 망막 영상 진단 기술의 발전, 그리고 전문적인 안과 의료 서비스에 대한 접근성 확대에 힘입어 성장하고 있으며, 이를 통해 조기 진단과 적시 치료가 가능해졌습니다. 항혈관내피성장인자(anti-VEGF) 요법은 여전히 신생혈관성(습성) 노인성 황반변성의 표준 치료법으로 자리 잡고 있으나, 보체 경로 억제제의 도입으로 건성 노인성 황반변성에서 지리적 위축에 대한 치료 선택의 폭이 넓어지고 있습니다. 서방형 약물전달 시스템, 유전자 치료 및 신규 생물학적 제제에 대한 지속적인 연구 개발을 통해 개발 파이프라인이 강화되고 있으며, 치료 부담 경감이라는 요구에 부응하기 위한 노력이 진행되고 있습니다. 동시에, 의료비 증가, 개발도상국의 망막 의료 인프라 확충, 그리고 제약 및 생명공학 기업의 안과 분야 진출 확대가 선진국과 신흥 지역 모두에서 시장의 꾸준한 성장을 뒷받침하고 있습니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 노인황반변성 시장 : 변수, 동향, 범위
제4장 노인황반변성 시장 : 제품별 비즈니스 분석
제5장 노인황반변성 시장 : 질환별 비즈니스 분석
제6장 노인황반변성 시장 : 유통 채널별 비즈니스 분석
제7장 노인황반변성 시장 : 지역별 추정·동향 분석
제8장 경쟁 구도
KSMAge-related Macular Degeneration Market Summary
The global age-related macular degeneration market size was valued at USD 11.6 billion in 2025 and is projected to grow from USD 12.5 billion in 2026 to USD 22.7 billion by 2033, at a CAGR of 9.0% from 2026 to 2033. The market in North America dominated with a revenue share of 53.9% in 2025. The market is driven by the increasing burden of the aging population, as AMD remains one of the leading causes of irreversible vision loss among older adults.
The market is supported by growing disease awareness, improvements in retinal imaging technologies such as optical coherence tomography (OCT), and broader access to specialist ophthalmology services, enabling earlier diagnosis and timely treatment. Anti-vascular endothelial growth factor (anti-VEGF) therapies remain the standard of care for neovascular (wet) AMD, while the introduction of complement pathway inhibitors has expanded treatment options for geographic atrophy in dry AMD. Ongoing research in sustained-release drug delivery systems, gene therapies, and novel biologics is strengthening the development pipeline and addressing the need to reduce treatment burden. At the same time, increasing healthcare expenditure, expanding retinal care infrastructure in developing countries, and the growing involvement of pharmaceutical and biotechnology companies in ophthalmology are supporting steady market growth across both developed and emerging regions.
Global Age-related Macular Degeneration Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global Age-related macular degeneration market report based on product, disease, distribution channel, and region:
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Eylea
- Lucentis
- Beovu
- Others
- Disease Outlook (Revenue, USD Million, 2021 - 2033)
- Wet AMD
- Dry AMD
- Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Disease
- 1.2.3. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Age-related Macular Degeneration Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
Chapter 4. Age-related Macular Degeneration Market: Product Business Analysis
- 4.1. Product Market Share, 2025 & 2033
- 4.2. Product Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Billion)
- 4.4. Eylea
- 4.4.1. Eylea Market, 2021 - 2033 (USD Billion)
- 4.5. Lucentis
- 4.5.1. Lucentis Market, 2021 - 2033 (USD Billion)
- 4.6. Beovu
- 4.6.1. Beovu Market, 2021 - 2033 (USD Billion)
- 4.7. Others
- 4.7.1. Others Market, 2021 - 2033 (USD Billion)
Chapter 5. Age-related Macular Degeneration Market: Disease Business Analysis
- 5.1. Disease Market Share, 2025 & 2033
- 5.2. Disease Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Disease, 2021 to 2033 (USD Billion)
- 5.4. Wet AMD
- 5.4.1. Wet AMD Market, 2021 - 2033 (USD Billion)
- 5.5. Dry AMD
- 5.5.1. Dry AMD Market, 2021 - 2033 (USD Billion)
Chapter 6. Age-related Macular Degeneration Market: Distribution Channel Business Analysis
- 6.1. Distribution Channel Market Share, 2025 & 2033
- 6.2. Distribution Channel Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Billion)
- 6.4. Hospital Pharmacy
- 6.4.1. Hospital Pharmacy Market, 2021 - 2033 (USD Billion)
- 6.5. Retail Pharmacy
- 6.5.1. Retail Pharmacy Market, 2021 - 2033 (USD Billion)
- 6.6. Online Pharmacy
- 6.6.1. Online Pharmacy Market, 2021 - 2033 (USD Billion)
Chapter 7. Age-related Macular Degeneration Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2025 & 2033
- 7.2. Regional Market Dashboard
- 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
- 7.4. North America
- 7.4.1. North America Age-related Macular Degeneration Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Target Disease Prevalence
- 7.4.2.3. Regulatory Framework
- 7.4.2.4. Reimbursement Framework
- 7.4.2.5. U.S. Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Target Disease Prevalence
- 7.4.3.3. Regulatory Framework
- 7.4.3.4. Reimbursement Framework
- 7.4.3.5. Canada Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.4.4. Mexico
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Target Disease Prevalence
- 7.4.4.3. Regulatory Framework
- 7.4.4.4. Reimbursement Framework
- 7.4.4.5. Mexico Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5. Europe
- 7.5.1. Europe Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Target Disease Prevalence
- 7.5.2.3. Regulatory Framework
- 7.5.2.4. Reimbursement Framework
- 7.5.2.5. UK Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.3. Germany
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Target Disease Prevalence
- 7.5.3.3. Regulatory Framework
- 7.5.3.4. Reimbursement Framework
- 7.5.3.5. Germany Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.4. France
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Target Disease Prevalence
- 7.5.4.3. Regulatory Framework
- 7.5.4.4. Reimbursement Framework
- 7.5.4.5. France Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.5. Italy
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Target Disease Prevalence
- 7.5.5.3. Regulatory Framework
- 7.5.5.4. Reimbursement Framework
- 7.5.5.5. Italy Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.6. Spain
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Target Disease Prevalence
- 7.5.6.3. Regulatory Framework
- 7.5.6.4. Reimbursement Framework
- 7.5.6.5. Spain Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.7. Denmark
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Target Disease Prevalence
- 7.5.7.3. Regulatory Framework
- 7.5.7.4. Reimbursement Framework
- 7.5.7.5. Denmark Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.8. Sweden
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Target Disease Prevalence
- 7.5.8.3. Regulatory Framework
- 7.5.8.4. Reimbursement Framework
- 7.5.8.5. Sweden Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.5.9. Norway
- 7.5.9.1. Key Country Dynamics
- 7.5.9.2. Target Disease Prevalence
- 7.5.9.3. Regulatory Framework
- 7.5.9.4. Reimbursement Framework
- 7.5.9.5. Norway Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6.2. Japan
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Target Disease Prevalence
- 7.6.2.3. Regulatory Framework
- 7.6.2.4. Reimbursement Framework
- 7.6.2.5. Japan Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6.3. China
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Target Disease Prevalence
- 7.6.3.3. Regulatory Framework
- 7.6.3.4. Reimbursement Framework
- 7.6.3.5. China Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6.4. India
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Target Disease Prevalence
- 7.6.4.3. Regulatory Framework
- 7.6.4.4. Reimbursement Framework
- 7.6.4.5. India Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6.5. Australia
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Target Disease Prevalence
- 7.6.5.3. Regulatory Framework
- 7.6.5.4. Reimbursement Framework
- 7.6.5.5. Australia Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6.6. South Korea
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Target Disease Prevalence
- 7.6.6.3. Regulatory Framework
- 7.6.6.4. Reimbursement Framework
- 7.6.6.5. South Korea Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.6.7. Thailand
- 7.6.7.1. Key Country Dynamics
- 7.6.7.2. Target Disease Prevalence
- 7.6.7.3. Regulatory Framework
- 7.6.7.4. Reimbursement Framework
- 7.6.7.5. Thailand Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.7. Latin America
- 7.7.1. Latin America Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Target Disease Prevalence
- 7.7.2.3. Regulatory Framework
- 7.7.2.4. Reimbursement Framework
- 7.7.2.5. Brazil Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Target Disease Prevalence
- 7.7.3.3. Regulatory Framework
- 7.7.3.4. Reimbursement Framework
- 7.7.3.5. Argentina Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Target Disease Prevalence
- 7.8.2.3. Regulatory Framework
- 7.8.2.4. Reimbursement Framework
- 7.8.2.5. South Africa Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Target Disease Prevalence
- 7.8.3.3. Regulatory Framework
- 7.8.3.4. Reimbursement Framework
- 7.8.3.5. Saudi Arabia Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.8.4. UAE
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Target Disease Prevalence
- 7.8.4.3. Regulatory Framework
- 7.8.4.4. Reimbursement Framework
- 7.8.4.5. UAE Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 7.8.5. Kuwait
- 7.8.5.1. Key Country Dynamics
- 7.8.5.2. Target Disease Prevalence
- 7.8.5.3. Regulatory Framework
- 7.8.5.4. Reimbursement Framework
- 7.8.5.5. Kuwait Age-related Macular Degeneration Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 8. Competitive Landscape
- 8.1. Participant Overview
- 8.2. Company Market Position Analysis
- 8.3. Company Categorization
- 8.4. Strategy Mapping
- 8.5. Company Profiles/Listing
- 8.5.1. Novartis AG
- 8.5.1.1. Overview
- 8.5.1.2. Financial Performance
- 8.5.1.3. Product Benchmarking
- 8.5.1.4. Strategic Initiatives
- 8.5.2. Bayer AG
- 8.5.2.1. Overview
- 8.5.2.2. Financial Performance
- 8.5.2.3. Product Benchmarking
- 8.5.2.4. Strategic Initiatives
- 8.5.3. Pfizer Inc.
- 8.5.3.1. Overview
- 8.5.3.2. Financial Performance
- 8.5.3.3. Product Benchmarking
- 8.5.3.4. Strategic Initiatives
- 8.5.4. F. Hoffmann-La Roche Ltd.
- 8.5.4.1. Overview
- 8.5.4.2. Financial Performance
- 8.5.4.3. Product Benchmarking
- 8.5.4.4. Strategic Initiatives
- 8.5.5. Bausch Health Companies Inc.
- 8.5.5.1. Overview
- 8.5.5.2. Financial Performance
- 8.5.5.3. Product Benchmarking
- 8.5.5.4. Strategic Initiatives
- 8.5.6. Regeneron Pharmaceuticals Inc.
- 8.5.6.1. Overview
- 8.5.6.2. Financial Performance
- 8.5.6.3. Product Benchmarking
- 8.5.6.4. Strategic Initiatives
- 8.5.7. Amgen Inc.
- 8.5.7.1. Overview
- 8.5.7.2. Financial Performance
- 8.5.7.3. Product Benchmarking
- 8.5.7.4. Strategic Initiatives
- 8.5.8. Biogen
- 8.5.8.1. Overview
- 8.5.8.2. Financial Performance
- 8.5.8.3. Product Benchmarking
- 8.5.8.4. Strategic Initiatives
- 8.5.9. Samsung Bioepis
- 8.5.9.1. Overview
- 8.5.9.2. Financial Performance
- 8.5.9.3. Product Benchmarking
- 8.5.9.4. Strategic Initiatives
- 8.5.1. Novartis AG
